The positive Phase 3 study results for Pluvicto and the announcement of its label expansion filing plans are likely to boost investor confidence in Novartis's growth prospects, particularly in the oncology segment. The acquisition of MorphoSys further strengthens its position in the cancer drug market, potentially leading to increased investor interest and a positive short-term impact on NVS stock price. The reported sales of $980 million from Pluvicto in 2023 also underline the drug's financial significance to Novartis.